Cytochrome P450 3A4 (abbreviated
CYP3A4) a member of the
cytochrome P450 mixed-function oxidase system, is one of the most important enzymes involved in the metabolism of
xenobiotics in the body. CYP3A4 is involved in the oxidation of the largest range of substrates of all the
CYPs. CYP3A4 is also, correspondingly, present in the largest quantity of all the CYPs in the
liver.
Fetuses do not express CYP3A4 in their liver/tissues; but rather CYP3A7, which acts on a similar range of substrates. CYP3A7 is gradually replaced by CYP3A4 in the developing neonate.
Distribution
Although CYP3A4 is predominantly found in the liver, it is also present in other organs and tissues of the body where it may play an important role in metabolism. CYP3A4 in the intestine plays an important role in the metabolism of certain drugs. Often this allows
prodrugs to be activated and absorbed - as in the case of the histamine
H1-receptor antagonist terfenadine.
Recently CYP3A4 has also been identified in the brain, however its role in the CNS is still unknown.
Variability
While over 28
single nucleotide polymorphisms (SNPs) have been identified in the
CYP3A4 gene, it has been found that this does not translate into significant interindividual variability
in vivo. It can be supposed that this may be due to the induction of CYP3A4 on exposure to substrates.
Variability in CYP3A4 function can be determined noninvasively by the erythromycin breath test (ERMBT). The ERMBT estimates in vivo CYP3A4 activity by measuring the radiolabelled carbon dioxide exhaled after an intravenous dose of (14C-N-methyl)-erythromycin.
Induction
CYP3A4 is
induced by a wide variety of
ligands. These ligands bind to the
Pregnane X Receptor (PXR). The activated PXR complex forms a heterodimer with the
Retinoid X Receptor (RXR) which binds to the
XREM region of the
CYP3A4 gene. XREM is a regulatory region of the
CYP3A4 gene, and binding causes a cooperative interaction with proximal promoter regions of the gene, resulting in increased transcription and expression of CYP3A4.
CYP3A4 ligands
Selected inducers, inhibitors and substrates of CYP3A4
| Substrates
| Inhibitors
| Inducers |
| Often mentioned:
Other: - protease inhibitors
- Mirtazapine (NaSSA)
- nefazodone (5-HT2A receptor antagonist)
- pimozide (antipsychotic)
- reboxetine (antidepressant)
- zopiclone (hypnotic)
- non-nucleoside reverse transcriptase inhibitors
- alfentanil (analgesic)
- budesonide (glucocorticoid)
- donepezil (acetylcholinesterase inhibitor)
- esomeprazole (proton pump inhibitor)
- omeprazole (proton pump inhibitor)
- finasteride (antiandrogen)
- glibenclamide (antidiabetic)
- cisapride (5-HT4 receptor agonist)
- terfenadine (H1-receptor antagonist)
- toremifene (SERM)
- barbiturates
- carbamazepine (anticonvulsant, mood stabilizing)
- codeine (analgesic, antitussive, antidiarrheal)
- dextromethorphan (antitussive)
- digoxin (Antiarrhythmic)
- ergot alkaloids (circulation, neurotransmission)
- estradiol (sex hormone)
- fentanyl (analgesic)
- ivabradine (in angina pectoris)
- levonorgestrel (hormonal contraceptive)
- lidocaine (local anesthetic, antiarrhythmic)
- methadone (analgesic, anti-addictive)
- mifepristone (abortifacient)
- montelukast (leukotriene receptor antagonist)
- ondansetron (5-HT3 antagonist)
- paracetamol (analgesic, antipyretic)
- quinidine (class I antiarrhythmic)
- quinine (antipyretic, anti-smallpox, analgesic)
- testosterone (androgen)
- theophylline (stimulant)
- valproate (anticonvulsant, mood-stabilizing)
- warfarin (anticoagulant)
- tetrahydrocannabinol (psychoactive)
- Antipsychotics
- Aripiprazole
- Risperidone
- Ziprasidone
| Strong:
unspecified: | Often mentioned: Other: |
References